- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03502174
FreeStyle Libre Glucose Monitoring System in Pediatric Populations
24. januar 2019 opdateret af: Abbott Diabetes Care
FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations
This study is a non-randomized, single-arm, multi-center study that is designed to evaluate the safety and effectiveness of the FreeStyle Libre Flash Glucose Monitoring Systems in pediatric populations.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Up to 85 subjects will be enrolled at up to four (4) clinical research sites in the United States.
Subjects will wear two Sensors.
Each Sensor will have a paired Reader that will be given to the subject.
All Readers will be masked during the study (i.e.
subjects will not be able to view glucose results obtained from the Sensor on the Reader screen).
Subjects will be asked to perform at least 4 capillary Blood Glucose (BG) tests per day using the primary Reader.
Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test.
Subjects will be instructed to report any problems with the device.
Subjects will make four (4) to five (5) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1).
Based on the subjects weight, subjects will have up to two (2) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
63
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
California
-
Santa Barbara, California, Forenede Stater, 93105
- Sansum Diabetes Research Institute
-
Walnut Creek, California, Forenede Stater, 94598
- Diablo Clinical Research
-
-
Idaho
-
Idaho Falls, Idaho, Forenede Stater, 83404
- Rocky Mountain Diabetes & Osteoporosis Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
6 år til 17 år (Barn)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Subjects aged 6-17 years, with type 1 or type 2 diabetes who currently perform capillary blood glucose (BG) testing at least four (4) times a day.
Beskrivelse
Inclusion Criteria:
- Subject must be at least 6 years of age.
- Subject must weigh at least 26 kg (57.2 lbs.).
- Subject must have a diagnosis of type 1 or type 2 diabetes mellitus
- Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).
- Subject must be currently performing at least four (4) capillary blood glucose tests per day.
- Subject is willing to perform a minimum of 4 finger sticks per day during the study.
- Subject is willing to allow medical personnel to insert at IV catheter in the arm to allow for venous blood samples to be obtained per the study protocol.
- Subject and/or guardian must be able to read and understand English.
- In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
- Subject must be available to participate in all study visits.
- Subject must be willing and able to provide written signed and dated informed assent when appropriate.
- Subject's parent, guardian or legally authorized representative must be willing and able to provide written informed consent.
Exclusion Criteria:
- Subject is 18 years of age or older.
- Subject weighs less than 26 kg (57.2 lbs.).
- Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
- Subject is known to be pregnant or becomes pregnant during the study (applicable to female subjects only).
- Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
- Subject is currently participating in another clinical trial.
- Subject has had significant blood loss within 112 days (3.7 months) prior to the beginning of the study activities subjects.
- Subject is anemic, defined as having hemoglobin levels below 11.5 g/dL for subjects aged 6-11 years old, less than 12.0 g/dL for subjects aged 12-15 years old, less than 12.0 g/dL for females aged 15-17 and less than 13.0 g/dL for males aged 15-171, or as determined by investigator.
- Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.
- Subject is unsuitable for participation due to any other cause as determined by the Investigator.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
FreeStyle Libre Flash Glucose Monitoring System Performance
Tidsramme: up to 14 days
|
System performance will be characterized with respect to YSI reference venous plasma sample measurements.
Point accuracy of the system will be evaluated as the proportion of System readings that are within ±20% of the YSI reference value for YSI glucose levels ≥ 80 mg/dl and within ±20 mg/dl for YSI glucose levels <80 mg/dl.
|
up to 14 days
|
|
FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects
Tidsramme: up to 45 days
|
System will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.
|
up to 45 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: Shridhara Alva, PhD, Abbot Diabetes care inc.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
5. april 2018
Primær færdiggørelse (Faktiske)
3. juli 2018
Studieafslutning (Faktiske)
3. juli 2018
Datoer for studieregistrering
Først indsendt
4. april 2018
Først indsendt, der opfyldte QC-kriterier
17. april 2018
Først opslået (Faktiske)
18. april 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
28. januar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. januar 2019
Sidst verificeret
1. april 2018
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- ADC-US-VAL-18172
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ja
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus
-
State University of New York at BuffaloMedical University of South CarolinaAfsluttetDiabetes mellitus | Type 2 diabetes mellitus | Voksen-debuterende diabetes mellitus | Ikke-insulinafhængig diabetes mellitus | Ikke-insulinafhængig diabetes mellitus, type IIForenede Stater
-
Meir Medical CenterAfsluttetDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, om oral hypoglykæmisk behandling | Voksen type diabetes mellitusIsrael
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
SanofiAfsluttetType 1-diabetes mellitus-type 2-diabetes mellitusUngarn, Den Russiske Føderation, Tyskland, Polen, Japan, Forenede Stater, Finland
-
Medtronic MiniMed, Inc.RekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitusForenede Stater, Australien, New Zealand
-
Peking Union Medical College HospitalUkendtType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskabsdiabetes mellitus | Pancreatogen diabetes mellitus | Prægestationsdiabetes mellitus | Diabetespatienter i perioperativ periodeKina
-
Insulet CorporationRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitusForenede Stater
-
State University of New York at BuffaloMedical University of South Carolina; National Institute of Diabetes and...AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pancreatogen diabetes | Lægemiddel-induceret diabetes mellitus | Andre former for diabetes mellitusKina
Kliniske forsøg med FreeStyle Libre Flash Glucose Monitoring System
-
Abbott Diabetes CareAfsluttetDiabetes mellitusDet Forenede Kongerige, Tyskland, Irland
-
Abbott Diabetes CareAfsluttetDiabetes mellitusForenede Stater
-
Abbott Diabetes CareAfsluttet
-
Abbott Diabetes CareAfsluttet
-
Abbott Diabetes CareAfsluttetDiabetes mellitusForenede Stater
-
Abbott Diabetes CareAfsluttetDiabetes mellitusForenede Stater
-
Abbott Diabetes CareAfsluttetDiabetes mellitusForenede Stater
-
Abbott Diabetes CareAfsluttetDiabetes mellitusForenede Stater
-
Abbott Diabetes CareAfsluttet
-
Abbott Diabetes CareAfsluttetDiabetes mellitusDet Forenede Kongerige